| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
LeukoVantage®, Myeloid
Test Code39194
CPT Codes
81450
Preferred Specimen
5 mL whole blood or bone marrow collected in an EDTA (lavender-top) tube
Minimum Volume
2 mL whole blood or bone marrow • 20 uL of 10 ng/uL extracted DNA
Other Acceptable Specimens
Whole blood or bone marrow collected in: Sodium heparin (green-top) tube • 50 uL of 10 ng/uL extracted DNA in microcentrifuge tube • Fixed pellet collected in a sterile leak-proof container
Instructions
Requisition form and Pathology/Flow Cytometry Report are required.
In addition, only accept extracted DNA when extraction or isolation is performed in an appropriately qualified laboratory such as a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/ or CMS.
In addition, only accept extracted DNA when extraction or isolation is performed in an appropriately qualified laboratory such as a CLIA-certified laboratory or a laboratory meeting equivalent requirements as determined by the CAP and/ or CMS.
Transport Temperature
Room temperature
Specimen Stability
Whole blood and bone marrow (EDTA)
Room temperature: 14 days
Refrigerated: 14 days
Frozen: Unacceptable
Whole blood and bone marrow (Sodium heparin)
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
Extracted DNA
Room temperature: 30 days
Refrigerated: 2 years
Frozen: Indefinite
Fixed cell pellet
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
Room temperature: 14 days
Refrigerated: 14 days
Frozen: Unacceptable
Whole blood and bone marrow (Sodium heparin)
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
Extracted DNA
Room temperature: 30 days
Refrigerated: 2 years
Frozen: Indefinite
Fixed cell pellet
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Gross hemolysis • Clotted blood sample
Methodology
Next Generation Sequencing
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Tues, Thurs; Report available: 10-14 days
Clinical Significance
This test is designed to aid in diagnosis, prognosis and/or treatment strategy for patients with AML, MPN and MDS.
